Details for New Drug Application (NDA): 020677
✉ Email this page to a colleague
The generic ingredient in ZAGAM is sparfloxacin. Additional details are available on the sparfloxacin profile page.
Summary for 020677
| Tradename: | ZAGAM |
| Applicant: | Mylan |
| Ingredient: | sparfloxacin |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 200MG | ||||
| Approval Date: | Dec 19, 1996 | TE: | RLD: | No | |||||
Expired US Patents for NDA 020677
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mylan | ZAGAM | sparfloxacin | TABLET;ORAL | 020677-001 | Dec 19, 1996 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
